Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Step-up from Seretide Diskus to CHF5993 DPI assessed by functional respiratory imaging in advanced COPD
2020-002356-20Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium and salmeterol + fluticasone in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Percentage change from baseline in untrimmed specific airway volume during inspiration. Started Mar 2021; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrroniumsalmeterol + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2020-002356-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002356-20.